Replies to post #109250 on Biotech Values

[linhdtu]

<Again imputing something to me that is highly suspect - that I love the term 'paradigm shift'. And then hinting that only physician's are entitled to medical opinions? Or some other form of stereotyping? Really? On a board where >50% of the interesting analysis posts are written by non medical/researcher "professionals" (well, ok, that's kinda cheating since Dew posts more than anyone else on the board by a large amount -g-)
>

I believe I have seen that line of reasoning before. An econ from the Fed Reserve Board wrote an opinion on WSJ (I think) that because most opinions written on financial blogs are written by people not trained in economics, basically it is gibberish they are presenting to the public.

[vinmantoo]

<Again imputing something to me that is highly suspect - that I love the term 'paradigm shift'. And then hinting that only physician's are entitled to medical opinions? Or some other form of stereotyping? Really? On a board where >50% of the interesting analysis posts are written by non medical/researcher "professionals" (well, ok, that's kinda cheating since Dew posts more than anyone else on the board by a large amount -g-)>


iwfal,

Obviously you can post and invest in biotech without a science or medical background. I wasn't attacking or questioning the right of some not in science to post, I was just wondering why the term "paradigm shift" becomes an important defense of why one owns a company. I believe that you did use it so that was the source of my comments. I take it from your responses that you don't have a science background so my advice is to regard anyone who resorts to buzz words like "paradigm shift" as an excuse for problems a company is experiencing as a red flag. I will say I do have a science background and I was too blinded by my love of technological advances that I failed to see what a looming disaster GTCB was. Take my advice and admonitions as a warning based on my own failures. Obviously DNDN is different from GTCB, but if Provenge production facilities and Provenge sales continue to fall behind projections and cash reserves continue to rapidly dwindle, be more skeptical of the "paradigm shift" excuse.